1. Home
  2. ENTX vs CSBR Comparison

ENTX vs CSBR Comparison

Compare ENTX & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • CSBR
  • Stock Information
  • Founded
  • ENTX 2010
  • CSBR 1985
  • Country
  • ENTX Israel
  • CSBR United States
  • Employees
  • ENTX N/A
  • CSBR N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • CSBR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ENTX Health Care
  • CSBR Health Care
  • Exchange
  • ENTX Nasdaq
  • CSBR Nasdaq
  • Market Cap
  • ENTX 67.2M
  • CSBR 65.9M
  • IPO Year
  • ENTX 2018
  • CSBR 1986
  • Fundamental
  • Price
  • ENTX $1.73
  • CSBR $4.50
  • Analyst Decision
  • ENTX Strong Buy
  • CSBR Strong Buy
  • Analyst Count
  • ENTX 1
  • CSBR 1
  • Target Price
  • ENTX $10.00
  • CSBR $6.00
  • AVG Volume (30 Days)
  • ENTX 127.7K
  • CSBR 11.7K
  • Earning Date
  • ENTX 11-08-2024
  • CSBR 12-10-2024
  • Dividend Yield
  • ENTX N/A
  • CSBR N/A
  • EPS Growth
  • ENTX N/A
  • CSBR N/A
  • EPS
  • ENTX N/A
  • CSBR N/A
  • Revenue
  • ENTX $99,000.00
  • CSBR $51,655,000.00
  • Revenue This Year
  • ENTX N/A
  • CSBR $9.27
  • Revenue Next Year
  • ENTX N/A
  • CSBR $9.76
  • P/E Ratio
  • ENTX N/A
  • CSBR N/A
  • Revenue Growth
  • ENTX 607.14
  • CSBR N/A
  • 52 Week Low
  • ENTX $0.52
  • CSBR $3.60
  • 52 Week High
  • ENTX $3.35
  • CSBR $7.13
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 44.32
  • CSBR 54.07
  • Support Level
  • ENTX $1.64
  • CSBR $4.30
  • Resistance Level
  • ENTX $1.80
  • CSBR $4.70
  • Average True Range (ATR)
  • ENTX 0.09
  • CSBR 0.24
  • MACD
  • ENTX -0.01
  • CSBR 0.06
  • Stochastic Oscillator
  • ENTX 30.00
  • CSBR 78.95

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About CSBR Champions Oncology Inc.

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

Share on Social Networks: